Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
This study has been completed.
Study NCT01000961   Information provided by Raptor Therapeutics Inc.

First Received on October 22, 2009.   Last Updated on September 17, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cystinosis
Additional conditions recognized in this trial
Fanconi Syndrome
More general conditions related to this trial
Genetic Diseases, Inborn
Kidney Diseases
Lysosomal Storage Diseases
Metabolic Diseases
Metabolism, Inborn Errors
Renal Tubular Transport, Inborn Errors
Urologic Diseases
Interventions listed in this trial
Cystagon® (Cysteamine Bitartrate)
Additional drug interventions recognized in this trial
Cysteamine
More general drug interventions related to this trial
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Radiation-Protective Agents
Sponsors listed in this trial
Raptor Therapeutics Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services